EA201991124A1 - ПИРРОЛЬНЫЕ АМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV - Google Patents
ПИРРОЛЬНЫЕ АМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αVInfo
- Publication number
- EA201991124A1 EA201991124A1 EA201991124A EA201991124A EA201991124A1 EA 201991124 A1 EA201991124 A1 EA 201991124A1 EA 201991124 A EA201991124 A EA 201991124A EA 201991124 A EA201991124 A EA 201991124A EA 201991124 A1 EA201991124 A1 EA 201991124A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- integrin inhibitors
- pharmaceutical compositions
- relates
- pyrrole amides
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title abstract 3
- 108010044426 integrins Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- -1 Pyrrole amides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418833P | 2016-11-08 | 2016-11-08 | |
| PCT/US2017/060392 WO2018089360A1 (en) | 2016-11-08 | 2017-11-07 | Pyrrole amides as alpha v integrin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991124A1 true EA201991124A1 (ru) | 2019-10-31 |
Family
ID=60409438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991124A EA201991124A1 (ru) | 2016-11-08 | 2017-11-07 | ПИРРОЛЬНЫЕ АМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10717736B2 (https=) |
| EP (1) | EP3538528B1 (https=) |
| JP (1) | JP7220653B2 (https=) |
| KR (1) | KR102515507B1 (https=) |
| CN (1) | CN110139864B (https=) |
| AU (1) | AU2017359030A1 (https=) |
| BR (1) | BR112019009293A2 (https=) |
| CA (1) | CA3042693A1 (https=) |
| CY (1) | CY1123893T1 (https=) |
| DK (1) | DK3538528T3 (https=) |
| EA (1) | EA201991124A1 (https=) |
| ES (1) | ES2852351T3 (https=) |
| HR (1) | HRP20210228T1 (https=) |
| HU (1) | HUE053620T2 (https=) |
| IL (1) | IL266469A (https=) |
| LT (1) | LT3538528T (https=) |
| MX (1) | MX377293B (https=) |
| PL (1) | PL3538528T3 (https=) |
| PT (1) | PT3538528T (https=) |
| RS (1) | RS61453B1 (https=) |
| SI (1) | SI3538528T1 (https=) |
| SM (1) | SMT202100089T1 (https=) |
| WO (1) | WO2018089360A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| AU2017359025A1 (en) * | 2016-11-08 | 2019-06-20 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha V integrin inhibitors |
| CN110177787A (zh) | 2016-12-29 | 2019-08-27 | 圣路易斯大学 | 整合素拮抗剂 |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MA47697A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| FI3844162T3 (fi) | 2018-08-29 | 2025-03-27 | Morphic Therapeutic Inc | Alfa v beeta6 -integriinin estäjiä |
| EP4086254B1 (en) | 2018-08-29 | 2024-12-18 | Morphic Therapeutic, Inc. | Integrin inhibitors |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| EP4541422A3 (en) | 2018-10-30 | 2025-06-25 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| KR102659859B1 (ko) | 2018-10-30 | 2024-04-25 | 길리애드 사이언시즈, 인코포레이티드 | 알파4β7 인테그린의 억제를 위한 화합물 |
| CN112969700B (zh) | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 作为α4β7整合素抑制剂的咪唑并吡啶衍生物 |
| KR102908219B1 (ko) | 2019-08-14 | 2026-01-08 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
| CR20230472A (es) * | 2021-03-10 | 2024-03-21 | Dice Molecules Sv Inc | Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| IL118325A0 (en) * | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
| EP1049693A1 (en) * | 1997-11-26 | 2000-11-08 | Du Pont Pharmaceuticals Company | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS |
| WO1999030709A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| CZ20003672A3 (cs) | 1998-04-10 | 2001-08-15 | G. D. Searle & Co. | Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu |
| WO2000009503A1 (en) | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| AUPP646598A0 (en) | 1998-10-12 | 1998-11-05 | Fujisawa Pharmaceutical Co., Ltd. | New processes for producing alpha-alanine derivative |
| DE19939981A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Neue Inhibitoren des Integrins alphavß3 |
| CZ20021508A3 (cs) * | 1999-11-08 | 2002-10-16 | Merck & Co., Inc. | Způsob výroby imidazolidinonových derivátů |
| GB0001447D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| NZ539682A (en) | 2001-01-29 | 2006-03-31 | Dimensional Pharm Inc | Substituted indoles and their use as integrin antagonists |
| DK1539739T3 (da) | 2002-08-16 | 2011-03-07 | Janssen Pharmaceutica Nv | Piperidinylforbindelser, der selektivt binder integriner |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| EP1667668B1 (en) | 2003-10-01 | 2008-07-02 | MERCK PATENT GmbH | Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents |
| WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
| EP2049490A1 (en) | 2006-06-09 | 2009-04-22 | Astra Zeneca AB | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| WO2011090929A1 (en) * | 2010-01-19 | 2011-07-28 | Theravance, Inc. | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents |
| ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
| NZ603789A (en) | 2010-05-26 | 2015-03-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| HRP20171873T1 (hr) * | 2013-02-07 | 2018-02-23 | Scifluor Life Sciences, Inc | Fluorinirani antagonisti integrina |
| GB201305668D0 (en) * | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| KR102647026B1 (ko) | 2015-02-19 | 2024-03-12 | 사이플루어 라이프 사이언시즈, 인크 | 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
-
2017
- 2017-11-07 SI SI201730618T patent/SI3538528T1/sl unknown
- 2017-11-07 KR KR1020197016078A patent/KR102515507B1/ko active Active
- 2017-11-07 MX MX2019005233A patent/MX377293B/es active IP Right Grant
- 2017-11-07 RS RS20210206A patent/RS61453B1/sr unknown
- 2017-11-07 AU AU2017359030A patent/AU2017359030A1/en not_active Abandoned
- 2017-11-07 US US16/347,826 patent/US10717736B2/en active Active
- 2017-11-07 EA EA201991124A patent/EA201991124A1/ru unknown
- 2017-11-07 PL PL17801236T patent/PL3538528T3/pl unknown
- 2017-11-07 HR HRP20210228TT patent/HRP20210228T1/hr unknown
- 2017-11-07 CN CN201780082138.2A patent/CN110139864B/zh active Active
- 2017-11-07 JP JP2019523772A patent/JP7220653B2/ja active Active
- 2017-11-07 EP EP17801236.5A patent/EP3538528B1/en active Active
- 2017-11-07 WO PCT/US2017/060392 patent/WO2018089360A1/en not_active Ceased
- 2017-11-07 HU HUE17801236A patent/HUE053620T2/hu unknown
- 2017-11-07 DK DK17801236.5T patent/DK3538528T3/da active
- 2017-11-07 BR BR112019009293A patent/BR112019009293A2/pt not_active Application Discontinuation
- 2017-11-07 CA CA3042693A patent/CA3042693A1/en not_active Abandoned
- 2017-11-07 PT PT178012365T patent/PT3538528T/pt unknown
- 2017-11-07 ES ES17801236T patent/ES2852351T3/es active Active
- 2017-11-07 SM SM20210089T patent/SMT202100089T1/it unknown
- 2017-11-07 LT LTEP17801236.5T patent/LT3538528T/lt unknown
-
2019
- 2019-05-06 IL IL266469A patent/IL266469A/en unknown
-
2021
- 2021-02-23 CY CY20211100149T patent/CY1123893T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102515507B1 (ko) | 2023-03-28 |
| MX377293B (es) | 2025-03-07 |
| JP7220653B2 (ja) | 2023-02-10 |
| US20190256512A1 (en) | 2019-08-22 |
| US10717736B2 (en) | 2020-07-21 |
| HRP20210228T1 (hr) | 2021-03-19 |
| SI3538528T1 (sl) | 2021-03-31 |
| KR20190076031A (ko) | 2019-07-01 |
| PT3538528T (pt) | 2021-02-16 |
| WO2018089360A1 (en) | 2018-05-17 |
| SMT202100089T1 (it) | 2021-03-15 |
| RS61453B1 (sr) | 2021-03-31 |
| DK3538528T3 (da) | 2021-02-15 |
| CY1123893T1 (el) | 2022-05-27 |
| CN110139864B (zh) | 2022-08-23 |
| BR112019009293A2 (pt) | 2019-07-30 |
| CN110139864A (zh) | 2019-08-16 |
| EP3538528A1 (en) | 2019-09-18 |
| ES2852351T3 (es) | 2021-09-13 |
| CA3042693A1 (en) | 2018-05-17 |
| MX2019005233A (es) | 2019-08-12 |
| IL266469A (en) | 2019-07-31 |
| LT3538528T (lt) | 2021-03-10 |
| HUE053620T2 (hu) | 2021-07-28 |
| JP2020500182A (ja) | 2020-01-09 |
| AU2017359030A1 (en) | 2019-06-20 |
| PL3538528T3 (pl) | 2021-05-31 |
| EP3538528B1 (en) | 2020-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991124A1 (ru) | ПИРРОЛЬНЫЕ АМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV | |
| EA201991127A1 (ru) | ЦИКЛОБУТАН- И АЗЕТИДИНСОДЕРЖАЩИЕ МОНО- И СПИРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНА αV | |
| EA201991122A1 (ru) | 3-ЗАМЕЩЕННЫЕ ПРОПАНОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНА αV | |
| EA201991121A1 (ru) | АЗОЛАМИДЫ И АЗОЛАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV | |
| EA201991123A1 (ru) | ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV | |
| EA202091063A1 (ru) | Мостиковые бициклические соединения в качестве модуляторов фарнезоидного х-рецептора | |
| EA201991412A1 (ru) | Ингибиторы поли(адф-рибоза)полимеразы (parp) | |
| EA201691471A1 (ru) | Макроциклы с гетероциклическими группами p2' как ингибиторы фактора xia | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| EA201792536A1 (ru) | Триазоловые агонисты рецептора apj | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| MX2019008122A (es) | Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1. | |
| EA201691404A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов бромодомена | |
| EA201790817A1 (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 для лечения болезни альцгеймера | |
| EA201790818A1 (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 | |
| EA201791030A1 (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
| EA202091136A1 (ru) | Производные пирролопиразина в качестве ингибиторов альфа-v интегрина | |
| EA201992370A1 (ru) | Соединения и способы для лечения бактериальных инфекций |